DiaMedica Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de DiaMedica Therapeutics es Rick Pauls , nombrado en Jan 2010, tiene una permanencia de 14.83 años. compensación anual total es $1.22M, compuesta por 46.2% salario y 53.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.16% de las acciones de la empresa, por valor de $286.70K. La antigüedad media del equipo directivo y de la junta directiva es de 2.2 años y 5.5 años, respectivamente.
Información clave
Rick Pauls
Chief Executive Officer (CEO)
US$1.2m
Compensación total
| Porcentaje del salario del CEO | 46.2% |
| Permanencia del CEO | 14.8yrs |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 2.2yrs |
| Promedio de permanencia en la Junta Directiva | 5.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
Nov 23
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
May 16We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 12FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
Jul 06We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Jun 16We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 04DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
Nov 05DiaMedica: Undercovered Stroke Drug Company With Decent Data
Jun 13We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
May 01Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?
Feb 13
We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn
Jan 09DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$22m |
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$19m |
| Dec 31 2023 | US$1m | US$562k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$18m |
| Jun 30 2023 | n/a | n/a | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$15m |
| Dec 31 2022 | US$1m | US$523k | -US$14m |
| Sep 30 2022 | n/a | n/a | -US$13m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$1m | US$477k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$878k | US$455k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | US$2m | US$420k | -US$11m |
| Sep 30 2019 | n/a | n/a | -US$10m |
| Jun 30 2019 | n/a | n/a | -US$9m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$734k | US$315k | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$5m |
| Jun 30 2018 | n/a | n/a | -US$4m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$502k | US$280k | -US$4m |
Compensación vs. Mercado: La compensación total ($USD1.22M) de Rick está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD1.46M).
Compensación vs. Ingresos: La compensación de Rick ha aumentado mientras la empresa no es rentable.
CEO
Rick Pauls (53 yo)
14.8yrs
Permanencia
US$1,215,161
Compensación
Mr. Dietrich John Pauls, also known as Rick, MBA has been Chief Executive Officer and President of DiaMedica Therapeutics Inc. since January 2010 and has been its Director since April 2005. Mr. Pauls was a...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 14.8yrs | US$1.22m | 0.16% $ 286.7k | |
| CFO & Corporate Secretary | 6.6yrs | US$632.22k | 0.075% $ 135.0k | |
| Chief Technology Officer | 1.2yrs | sin datos | sin datos | |
| Chief Commercial Officer | 2.8yrs | sin datos | 0.0066% $ 11.7k | |
| Chief Business Officer | 1.6yrs | sin datos | 1.23% $ 2.2m | |
| Chief Medical Officer | less than a year | sin datos | sin datos |
2.2yrs
Permanencia media
59yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de DMAC se considera experimentado (2.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 19.6yrs | US$1.22m | 0.16% $ 286.7k | |
| Independent Director | 9.1yrs | US$97.18k | 0.0053% $ 9.4k | |
| Independent Director | 14.3yrs | US$90.93k | 0.76% $ 1.3m | |
| Member of Kidney Scientific Advisory Board | 5.5yrs | sin datos | sin datos | |
| Independent Chairman | 15.5yrs | US$133.98k | 0.33% $ 591.3k | |
| Member of Kidney Scientific Advisory Board | 5.5yrs | sin datos | sin datos | |
| Member of Kidney Scientific Advisory Board | 5.5yrs | sin datos | sin datos | |
| Member of Stroke Advisory Board | 1.8yrs | sin datos | sin datos | |
| Member of Stroke Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Kidney Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Stroke Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Kidney Scientific Advisory Board | 5.5yrs | sin datos | sin datos |
5.5yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de DMAC se considera experimentada (5.5 años de antigüedad promedio).